Brits pillory Novo plans to withdraw drug; Teva posts 62% hike in Q3 profits;

@FiercePharma: FDA looks to prosecute 'two-legged defendants'. Article | Follow @FiercePharma

> Plans by Denmark's Novo Nordisk to withdraw an old insulin treatment were slammed by British diabetes experts, who said it would cause disruption to patients and push up costs. Report

> Teva Pharmaceutical Industries reported a 62 percent rise in third-quarter net profit to $1.05 billion, helped by growth in its generic operations and strong sales of flagship multiple-sclerosis drug Copaxone. Teva release | Article

> Eli Lilly failed to win an appeals court rehearing over its loss of patent protection for the cancer drug Gemzar. Report

> Acorda Therapeutics said fourth-quarter sales of its key drug Ampyra that accounted for about 80 percent of total revenue may fall sequentially, sending its shares down as much as 7 percent. News

> Impax Laboratories sued Shire to force the drugmaker to deliver the Adderall XR authorized generic supply provided for in the companies' 2006 patent settlement. Impax release

> As the third liability suit over Novartis' bone drugs plays out in court, the plaintiff's lawyer told jurors that company officials downplayed the risks that Aredia and Zometa could destroy patients' jaws. Story

> Allergan reported higher-than-expected quarterly sales of eye-care drugs and breast implants and raised its full-year outlook, sending its shares up more than 2 percent. Article

> Reckitt Benckiser lifted third quarter profits by a fifth and has raised it full year targets thanks to strong strong sales growth in developing markets and a full contribution from its prescription pharmaceuticals businesses. Report

Biotech News

 @FierceBiotech: In bombshell, DOJ reverses stance on gene patents. Report | Follow @FierceBiotech

 @JohnCFierce: Glaxo inks $231M pact for Phase III Amicus drug. Another rare disease pact for the pharma giant. Article  | Follow @JohnCFierce

> Ironwood takes big stride toward linaclotide NDA. News 

> Amgen proposes key hurdles for biosimilar regs. Article 

> Lilly blueprints plans for new R&D complex in China. Story 

> Waksal inks pair of hepatitis C pacts for his start-up. Report

> Amgen pays Nektar $50M for polymer. Article 

 Biotech Research News

> U.S. reverses stance on genes and patents. Story

> As Americans go to the polls, have genes already cast their votes? News

> U.K. scientists hail artificial liver progress. Report

> Study says docs often discount dad's side in breast cancer screening. Item

> Spencer, National Pharma develop CNS treatments. Article 

> Progress reported in 1,000 Genome Project. Report

Manufacturing News

> Heparin recall again traced to API supplier SPL. Item

> Pfizer fights Lipitor odor with plastic pallets. Story 

> Late October marks recall-o-rama. News

> Russia gaining on China in pharma spam. Article

> Roche cleaning up inherited contamination at NJ site. Report 

> J&J assumes QA inspector role at Crucell. News

And Finally... The U.S. Supreme Court agreed to use a case involving Stanford University and Roche to consider reinforcing the patent rights of research universities that rely on federal funds. Report

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.